Member Info for LiveLongnProsper

Yes, definitely worth a listen, Professor Gail Haywood Oxford University. Saliva tests discussed, early encouraging results in lab. But products being tested are via ‘CONDOR’, are we part of this?
GLA

Radio 4 08:34
Paraphrasing …
14 leading academics raise concerns about the rollout of antibody tests.
Performance of [antibody] tests not assessed.
Can’t show if people who have antibodies have immunity.
Also on the SP thread, the link to BBC news kind of defines antigen tests as ‘swab’ type tests, very poor research from the BBC. We need to get the message across about our strip test that will shortly dominate the market.
Just repeated on news headlines at 09:00, Professor Will Irvine, University of Nottingham – result of [antibody] test makes no difference to how individuals are managed.
GLA

"That made me laugh out loud"
Likewise, hilawious!

@Candid, there is an earlier thread, certainly worth keeping an eye these guys.
The BetterLife announcement on 19th June seems to suggest new clinical trials, clicking on the announcement link directs you to a page with the details of the trial (note the ‘uncontrolled’ nature) published on 15th of May.
If you look into BetterLife in a little more detail you will see that they are trying to acquire Altum who have the patent for AP-003 (inhaled IFNa2b) – BetterLife have certain rights in certain regions to manufacture and sell AP-003.
Phase 3 trials are planned to start July 2020 (early Covid-19 infection) and Q4 (lower dose for Prophylaxis / Prevention), see their latest investor presentation …
https://blifetherapeutics.com/wp-content/uploads/2020/05/BetterLife_Tharaputics.pdf
While our trials are phase 2, given that they are double-blind placebo controlled (first results from NHS setting, so ‘gold standard’) expedited approval on success would be reasonably expected. They will be starting their trials just as our results are released!
GLA

@mstar, agree, resolution 8 gives adequate authority for the issue of further shares, resolution 9 was separated out, maybe as a ‘discussion’ point (I wonder if it was actually voted on?), certainly stretching a point!
@DOH85, The General Meeting at 10:00am on 24th June will vote on a ‘Resolution’ concerned with the …
“Proposed placing of 8,669,682 Second Placing Shares”, “Proposed subscription for 914,215 Second Subscription Shares”, “Proposed subscription for 4,061,821 PrimaryBid Shares”.
No suggestion that the individual ‘placings’ are to be voted on separately. Voting against this after the recent (excellent) strategy presentations would seem like a very bad idea!
GLA

Govt. already moving to head off ...?
https://www.bbc.co.uk/news/business-53127737
GLA

Looks like the Chinese are on the lookout for innovative Biotech. Oxford Nanopore are primarily about genetic sequencing, but are developing their LamPORE technology for SARS-CoV-2 detection. US Biotech Amgen have a stake in the co.
https://www.telegraph.co.uk/technology/2020/06/19/chinese-firm-tencent-prepares-take-stake-british-biotech-firm/
Hope AVCT have got their IT security in good shape, wouldn’t want to ‘give’ anything away!
GLA

@NoLupus, Yep, BetterLife are trying to acquire Altum who have the patent for AP-003 (inhaled IFNa2b) – BetterLife have certain rights in certain regions to manufacture and sell AP-003. More trials are planned to start July 2020 (early Covid-19 infection) and Q4 (lower dose for Prophylaxis / Prevention).
https://blifetherapeutics.com/wp-content/uploads/2020/05/BetterLife_Tharaputics.pdf
They will be starting their trials just as our results are released!
GLA

Another announcement from BetterLife Pharma (19/06/20) on inhaled IFN-a-2b (vs. our IFN-ß-1a) …
https://abetterlifepharma.com/investors/#latestnews
Whereas the announcement seems to suggest new clinical trials, clicking on the announcement link directs you to a page with the details of the (uncontrolled) trial published on 15th of May.

I wonder if they are trying to get approval to use their formulation based on those results alone?

Why did they cancel, at 1 days notice, last weeks scheduled webinar with their new Scientific Advisory Board member Dr Eleanor Fish to discuss the use of IFN in treating Covid-19? Note that Dr Fish had been quoted as saying that "rather than developing a virus-specific antiviral for each new virus outbreak, I would argue that we should consider interferons as the 'first responders' in terms of treatment. Interferons have been approved for clinical use for many years, so the strategy would be to 'repurpose' them for severe acute virus infections…”.

I wonder if they know that someone else will shortly be announcing results from a double-blind placebo controlled trial of another formulation (SNG001!) of inhaled IFN?
GLA

No. of trades by range block …
15/06/20 - £7.29m for trades >= 25,000
5> 100,000, 12 = 100,000, 20 >50,000, 23 = 50,000, 44 > 25,000, 44 = 25,000
16/06/20 - £4.26m for trades >= 25,000
4 > 100,000, 8= 100,000, 4 > 50,000, 10 = 50,000, 30 > 25,000, 31 = 25,000
Trades (buys and sells) reported, including late reported.
(Source – LondonStockExchange site, please DYOR in case my numbers are ‘off’).
Something of a reduction in volume of large trades.
For a simple view of recent trades (as reported sequence) try Morningstar.
Perhaps positions taken for real action? And / or some stake building?
GLA

@SiriusB, no doubt stop losses will have been triggered, but some serious action, more than just PI's!.
Trades, in blocks …
5 > 100,000
2020-06-15T10:12:12.227 GBX 110 300155 330170.5 Off-Book AIMX LRGS
2020-06-15T09:30:59.053 GBX 110 200000 220000 Off-Book AIMX LRGS
2020-06-12T16:06:23.000 GBX 128 169488 216944.64 Off-Book XOFF N
2020-06-15T11:23:07.807 GBX 116 130000 150800 Off-Book AIMX LRGS
2020-06-15T08:09:35.377 GBX 116.28 113244 131680.1232 Off-Book AIMX LRGS
12 = 100,000, 20 >50,000, 23 = 50,000, 44 > 25,000, 44 = 25,000 – total 7.29m > = 25,000
Trades (buys and sells) reported, including late reported.
From LondonStockExchange daily trade download, but please DYOR as my counting might be off.
GLA

Ruane, Cunniff & Goldfarb and Conifer Management LLC are the Sequoia Fund’s investment advisers …
https://sec.report/Document/0001104659-20-052448/tm2013804d2_ex99-p1.htm
https://www.ruanecunniff.com/InvestmentOptions
Greg Alexander is a non-voting member of the Sequoia Fund investment committee and director of Conifer Management, who also run their own fund.
https://sec.report/Document/0000919574-20-003594/
I presume that Conifer Management LLC as the ‘person subject to the notification obligation’ (item 3. On the TR-1 RNS of 10/06/20) are acting on behalf of (as advisers to) the Sequoia Fund – as per Alastair’s confirmation.
Anecdotally, apparently, don’t quote me etc., Warren Buffett thinks Greg A. is pretty good, so looks like we’ve been specially selected by the ‘top guys’!
(Oh, and the Sequoia Fund and Sequoia Capital are not the same)
Of course please DYOR, corrections welcome, GLA

A few coming in now (source - morningstar)...
15:24 40.07 50,000 0.00 0.00 ? - - -
16:05 38.50 25,000 0.00 0.00 ? - - -
15:47 39.55 20,000 39.00 40.00 ? - - -
15:43 39.33 24,550 39.00 40.00 ? - - -
15:42 39.60 16,191 39.00 40.00 ? - - -

@RorkesDrift Agree, the Arix guy was very assured and on top of his brief, also said he would have liked AVCT in his portfolio if he could have (words to that effect).
Arix portfolio co. Harpoon Therapeutics has TriTAC which looked (to me anyway) like a possible competitor to Affimers. However despite being smaller than Antibodies I think they are much larger than Affimers.
Overall AS ‘stormed it’, good finish to the day and looks good for the next few.
GLA

@Retireby40, great points. @PL75, key question. I cannot find a direct link between ‘Sequoia Capital’ and ‘Sequoia Management’.
From my research …
Conifer Management LLC run their own fund managed by Greg Alexander, who is a non-voting member of the Sequoia Fund investment committee.
Conifer Management LLC are advisers to the Sequoia Fund – managed by Ruane, Cunniff & Goldfarb LLC.
Conifer Management LLC is the parent company of Acacia Partners LP – who have just acquired Link’s ex-Woodford Bio portfolio, causing interest on other boards (no doubt folks here also in SNG etc.)
Corrections, additions welcome.
GLA

Is this correct …?
Conifer Management LLC run their own $1.27bn fund managed by Greg Alexander, who is a non-voting member of the Sequoia Fund investment committee.
Conifer Management LLC is the parent company of Acacia Partners LP.
Conifer Management LLC are advisers to the Sequoia Fund (net assets $3.75bn) – managed by Ruane, Cunniff & Goldfarb LLC.
Could be an interesting few days, particularly with good news from Cytiva on the test …, haha!
Please DYOR
GLA

Yep, looks like 2 distinct trades for 180k ...
Jun 10 2020, 13:38 149.00 180,000 145.00 149.00 Buy £268,200.00000 O
Jun 10 2020, 16:31 149.074 180,000 144.00 145.00 Buy £268,333.2 O
GLA

At least someone got the message ... haha
Jun 10 2020, 13:38 149.00 180,000 145.00 149.00 Buy £268,200.00000 O
GLA

Covid-19 SG016 Hospital trial - Thur 28 May last trial patient recruited, 14 days dosing + 14 days follow-up to Thur 25 June, 3-4 weeks analysis of samples and data modelling etc. to Thur 16/23 July?
COPD SG015 trial – 26 May permission to conduct “unplanned interim analysis” of 109 (out of 120) patients, 3-4 weeks analysis to Tue 16/23 June?
So could see COPD results ahead of Covid-19, just days and a few weeks …
Probably flawed logic? Any variants on timings?
(Will be happy with Miles' 120p - for starters)
GLA

@Ophidian, @CautiousOptimist
Indeed your posts do not go unnoticed, please keep these rational, analytical, intelligent posts going.
Going to be an interesting week with 2 webinar sessions on Thursday.
In the meantime, some serious investors taking the opportunity (just a few examples) ...
Jun 9 2020, 09:42 130.00 20,000 129.00 130.00 Buy £26,000.0000 O
Jun 9 2020, 09:45 130.00 20,000 129.00 130.00 Buy £26,000.0000 O
Jun 9 2020, 09:52 127.55 10,000 127.00 128.00 Buy £12,755.0000 O
Jun 9 2020, 09:58 128.50 50,000 128.00 128.50 Buy £64,250.0000 O
Jun 9 2020, 09:58 128.50 50,000 128.00 128.50 Buy £64,250.0000 O not a duplicate
Jun 9 2020, 09:58 128.50 10,000 128.00 128.50 Buy £12,850.0000 O
GLA

GLA